
PCWG4 is published! #GU26 Thanks to @ThePCCTC and my co chairs Howard Scher and Mike Morrison and the 65 co-authors of these new trial guidelines! @DukeCancer @JCO_ASCO ascopubs.org/doi/10.1200/JCO…
✓
PCWG4 is published! #GU26 Thanks to @ThePCCTC and my co chairs Howard Scher and Mike Morrison and the 65 co-authors of these new trial guidelines! @DukeCancer @JCO_ASCO ascopubs.org/doi/10.1200/JCO…

We are proud to organize the 1st Nordic Meeting on Precision Medicine in Prostate Cancer. Copenhagen Sept 25-26. Please visit na.eventscloud.com/spcm2025

Prof @bjartell was honored with the Life Time Achievement Award at #EAU25 for his outstanding contributions to urology. 👏👏👏👏 A leading expert in #ProstateCancer, his research has advanced diagnostics and treatment. His legacy in science, mentorship, and innovation continues to shape the field. @OncoAlert @SigridCarlsson @amerseburger

Amazing time at #eau25 Madrid! Outstanding scientific program & great catching up w everyone! @SimaPorten @spsutkaMD @bjartell @JimCatto @shilpaonc @Caba_L @AStenzl @RenuEapen @carme_mir1 @GSK_UofT @CathyJPierce @DrJohnSfakianos @DrShariat @Tilki_De @mishabeltran @SumeetBhanvadia

🌟🔴 LIVE from #APCCC25! #APCCCDiagnostics25 📢 Imaging vs pathology—what matters more in prostate cancer? 🎤Important discussion by @ZilliThomas & @bjartell on pathology insights shaping clinical decisions! @APCCC_Lugano @OncoAlert @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin 💡 Key takeaways: 🔹 Lymph node involvement (LNI, pN1): The number of involved nodes predicts relapse; <3 positive nodes in ePLND is still debated. 🔹 Persistent PSA after RP: 5-20% have PSA ≥ 0.1 ng/mL post-RP—linked to worse OS, MFS, and CSS at 10-15 years. 🔹 Risk of recurrence: ISUP >2, pT3a/b, and positive surgical margins (PSM) increase biochemical recurrence risk. 🔹 AI & pathology: New digital pathology-based AI biomarkers predict adverse pathology and BCR! 👥 Expert panel: @bjartell @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt

Exciting to see the increasing applications of genetics and genomics for precision risk stratification & management of #prostatecancer - we are only at the beginning! -Nice talk by Attard #APCCCDiagnostics25 @OncoAlert

Nice talk on the limitations of conventional risk classifications used in #prostatecancer and using Decipher to improve risk stratification & treatment planning -@DrSpratticus #APCCCDiagnostics25 @OncoAlert

Presenting the sorely outdated NCCN risk groups @DrSpratticus #APCCCdiagnostics. Are they better than nothing? Sure. Can we do (much) better, for free, in 2025? Absolutely!

Voting results from the panel about use of genomic classifier testing in patients with localized prostate cancer and in patients with adverse prostatectomy pathology @Tilki_De #APCCCDiagnostics25 @OncoAlert

Delighted to be speaking here in #Lugano for the #APCCC. Really beautiful location, great talks. Looks like a win 🏆 for MRI in the diagnosis of patients with suspected prostate cancer. @BURSTurology @ESRUrology @BAUSurology @stefanofanti4 @ProfKHerrmann @LoebStacy


A GREAT DAY ONE #APCCCDiagnostics25 in Lugano🇨🇭 Here is Event Co-Organizer @stefanofanti4 🇮🇹 with a quick wrap up of DAY ONE and a Warm Invite to Join Us Tomorrow for DAY TWO of @APCCC_Lugano Diagnostics Scientific Committee @ProfKHerrmann 🇩🇪 @stefanofanti4 🇮🇹 @Silke_Gillessen 🇨🇭 @AOmlin 🇨🇭 Ambassadors @LoebStacy 🇺🇸 @ZilliThomas 🇨🇭 @nataliagandur 🇦🇷 @bavilima 🇧🇷 @fabioturco92 🇨🇭 @weoncologists 🇺🇸 The #APCCCDiagnostics Panel @bjartell @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt

Today we lost a dear friend and mentor. A brilliant mind and a generational talent with fire in his belly til the end. You will remain an eternal presence in my career and countless others in this community you have built. We mourn now, and then keep building for @felixfengmd.

RIP @felixfengmd great mentor and leader in urologic oncology. Remembering better days planning precision medicine trials with @DrPaulNguyen @DrSpratticus

So sad to hear about @felixfengmd passing away. A true giant of oncology but also the loveliest man you could ever hope to meet. A joy both to work with and to be with. His premature death a massive loss to humanity and a stark reminder why we do what we do. Rest in Peace 😢

Inspiring conference with brilliant minds dedicated to advancing prostate cancer research and patient outcomes. Discussing the role of biomarkers, genetics and MRI in prostate cancer screening. Thank you @OncLive and @DavidCrawfordMD for organizing! ✨ @samsimsal @prost8helf